Gland Pharma Limited — Investor Meet, 03-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Gland Pharma delivered a robust Q3 FY26 with revenue surging 22% YoY to INR 1,695.4 Cr and Adjusted EBITDA up 25% to INR 449 Cr (26% margin). Cenexi achieved positive EBITDA of EUR 1.4 million on EUR 50 million revenue, indicating a successful turnaround. The company anticipates 12-13% growth for FY27, aiming for 15% organic CAGR over 5 years. Strategic moves include expanding cartridge capacity from 40M to 140M units by Q2FY27 (for GLP-1s, insulin) and a new $25-30M oncology CDMO contract starting FY28. A substantial INR 2,000 Cr capex over five years is planned for base business and new lines. Management is confident, focusing on efficiency, R&D, and diversified offerings.